» Articles » PMID: 16212072

Current Perspective. Diabetic Vascular Disease: from Endothelial Dysfunction to Atherosclerosis

Overview
Journal Ital Heart J
Date 2005 Oct 11
PMID 16212072
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Cardiovascular complications are the leading cause of death in diabetes. Over the past decade a number of studies have addressed the underlying mechanisms. Derangements of endothelial function, also referred to as endothelial dysfunction, have emerged to be the crucial early step in the development of atherosclerosis and are also involved in plaque progression and clinical emergence. Endothelial dysfunction is a condition of impaired endothelium-dependent vasodilation and most important of "endothelial activation", characterized by a proinflammatory, proliferative, and procoagulatory milieu that promotes initiation and complications of atherogenesis. A synergistic cross-talk among the conventional cardiovascular risk factors associated with diabetes contributes to disruption of endothelial integrity and accelerated atherosclerosis. This review will focus on the multifactorial nature of endothelial dysfunction in diabetes, the relationship between endothelial dysfunction, conventional cardiovascular risk factors and atherosclerosis, and the therapeutic options to improve endothelial function.

Citing Articles

Which inflammatory marker, between systemic immune-inflammation index and neutrophil to eosinophil ratio, is associated with Peyronie's disease and are there any implications for a better understanding of its mechanisms?.

Crocetto F, Imbimbo C, Barone B, Turchino D, Bracale U, Peluso A Basic Clin Androl. 2023; 33(1):38.

PMID: 38110896 PMC: 10729439. DOI: 10.1186/s12610-023-00213-y.


CD144+ endothelial microparticles as a marker of endothelial injury in neonatal ABO blood group incompatibility.

Awad H, Tantawy A, El-Farrash R, Ismail E, Youssif N Blood Transfus. 2013; 12(2):250-9.

PMID: 24333075 PMC: 4039709. DOI: 10.2450/2013.0101-13.


Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and anti-atherogenic treatment in insulin resistant type 2 diabetes mellitus rats.

Sharma A, Raikwar S, Kurmi M, Srinivasan B Inflammopharmacology. 2012; 21(2):137-45.

PMID: 23111552 DOI: 10.1007/s10787-012-0154-4.